Fibrobiologics, Inc. (FBLG) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Fibrobiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based cell therapies for chronic diseases, including wound healing (CYWC628), multiple sclerosis (CYMS101), and degenerative disc disease (CybroCell). The company reported for the quarterly period ended June 30, 2025. As of this date, the company had 41,889,142 shares of Common Stock outstanding. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(4.66) million | $(9.62) million | $(7.56) million |
| Operating Expenses | $(4.49) million | $(9.02) million | $(6.67) million |
| Cash and Equivalents (End of Period) | $8.85 million | $8.85 million | $5.97 million |
| Short-Term Convertible Debt | $8.07 million | $8.07 million | $9.17 million |
| Accumulated Deficit | $(45.14) million | $(45.14) million | $(35.52) million |
Note: All figures in millions unless otherwise noted. The company has no revenue and operates at a loss.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2025, increased by $2.35 million (35%) compared to the same period in 2024. This was driven by a $1.89 million increase in Research and Development (R&D) expenses and a $0.46 million increase in General and Administrative (G&A) expenses.
- R&D Drivers: The increase in R&D was primarily due to higher Contract Research Organization (CRO) costs ($0.9 million) to prepare for clinical trials, increased personnel costs ($0.3 million), and higher research material expenses ($0.5 million).
- Debt Conversions: During the six months ended June 30, 2025, the company issued approximately 5.66 million shares of Common Stock upon the conversion of $5.8 million in principal of short-term convertible debt. This resulted in a net loss of approximately $0.4 million on the conversions.
- Stock Price Volatility Impact: Unlike the prior year, which saw significant non-cash gains from changes in fair value of warrant and forward contract liabilities, the current period saw minimal activity in these areas, with a small gain of $0.33 million from the change in fair value of convertible debt.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the issuance of the financial statements. The company has an accumulated deficit of $45.1 million and relies on raising additional capital to fund operations.
- Clinical Trial Delays: The planned Phase 1/2 clinical trial for CYWC628 (diabetic foot ulcers) in Australia has been delayed. Initiation is now expected in Q1 2026 (previously earlier) and completion in Q3 2026. Delays are attributed to resolving manufacturing process issues and sterility concerns with the Contract Development and Manufacturing Organization (CDMO).
- Nasdaq Compliance: On July 1, 2025, the company received a notification from Nasdaq that its closing bid price had been below $1.00 for 30 consecutive trading days. The company has an initial 180-day compliance period (until December 29, 2025) to regain compliance or risk delisting.
- Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties, as financial functions were handled by a limited number of individuals.
- Capital Resources: The company has a Standby Equity Purchase Agreement (SEPA) allowing it to require an investor to purchase up to an additional $10.0 million of shares. As of June 30, 2025, the company had $9.2 million in principal balance of outstanding debt.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.85 million cash balance against the burn rate of approximately $9.3 million over six months to assess immediate liquidity risk.
- Manufacturing Status: Confirm the resolution of sterility and process issues with the CDMO for CYWC628, as this is the critical path for the delayed Australian clinical trial.
- Debt Conversion Terms: Review the conversion prices of the outstanding convertible debt (floor prices and VWAP discounts) to understand potential future dilution, especially given the recent stock price decline.
- Nasdaq Compliance Plan: Monitor the company's strategy to regain the $1.00 minimum bid price requirement before the December 29, 2025 deadline to avoid delisting.
- Internal Controls: Assess the remediation plan for the identified material weakness in internal controls over financial reporting.